155 related articles for article (PubMed ID: 29573977)
1. Triple Negative Apocrine Carcinomas as a Distinct Subtype of Triple Negative Breast Cancer: A Case-control Study.
Meattini I; Pezzulla D; Saieva C; Bernini M; Orzalesi L; Sanchez LJ; Desideri I; Francolini G; Bonomo P; Greto D; Loi M; Mangoni M; Bruni A; Nori J; Vezzosi V; Bianchi S; Livi L
Clin Breast Cancer; 2018 Oct; 18(5):e773-e780. PubMed ID: 29573977
[TBL] [Abstract][Full Text] [Related]
2. Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers.
Arciero CA; Diehl AH; Liu Y; Sun Q; Gillespie T; Li X; Subhedar P
J Surg Oncol; 2020 Nov; 122(6):1232-1239. PubMed ID: 32668059
[TBL] [Abstract][Full Text] [Related]
3. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
Wu W; Wu M; Peng G; Shi D; Zhang J
Cancer Med; 2019 Dec; 8(18):7523-7531. PubMed ID: 31642210
[TBL] [Abstract][Full Text] [Related]
4. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
5. Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer.
Kim JY; Park S; Cho EY; Lee JE; Jung HH; Chae BJ; Kim SW; Nam SJ; Cho SY; Park YH; Ahn JS; Lee S; Im YH
Exp Mol Med; 2023 Jul; 55(7):1451-1461. PubMed ID: 37394589
[TBL] [Abstract][Full Text] [Related]
6. Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers.
Mills AM; E Gottlieb C; M Wendroth S; M Brenin C; Atkins KA
Am J Surg Pathol; 2016 Aug; 40(8):1109-16. PubMed ID: 27259012
[TBL] [Abstract][Full Text] [Related]
7. Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas.
Sun X; Zuo K; Yao Q; Zhou S; Shui R; Xu X; Bi R; Yu B; Cheng Y; Tu X; Lu H; Yang W
Mod Pathol; 2020 Dec; 33(12):2473-2482. PubMed ID: 32504034
[TBL] [Abstract][Full Text] [Related]
8. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
D'Arcy C; Quinn CM
J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Montagna E; Cancello G; Pagan E; Bagnardi V; Munzone E; Dellapasqua S; Viale G; Mazzarol G; Veronesi P; Galimberti V; Santomauro G; Colleoni M
Breast; 2020 Oct; 53():138-142. PubMed ID: 32795829
[TBL] [Abstract][Full Text] [Related]
10. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.
Schwartz CJ; Ruiz J; Bean GR; Sirohi D; Joseph NM; Hosfield EM; Jacobs TW; Mukhtar RA; Chen YY; Krings G
Mod Pathol; 2023 May; 36(5):100125. PubMed ID: 36870308
[TBL] [Abstract][Full Text] [Related]
11. Triple-Negative Apocrine Breast Carcinoma Has Better Prognosis despite Poor Response to Neoadjuvant Chemotherapy.
Hu T; Liu Y; Wu J; Hu XL; Zhao G; Liang B; Wang S; Long M
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329934
[TBL] [Abstract][Full Text] [Related]
12. An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast.
Vranic S; Gatalica Z
Clin Breast Cancer; 2022 Jun; 22(4):e576-e585. PubMed ID: 35027319
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: A large population-based analysis.
Zhao S; Ma D; Xiao Y; Jiang YZ; Shao ZM
Eur J Surg Oncol; 2018 Apr; 44(4):420-428. PubMed ID: 29429597
[TBL] [Abstract][Full Text] [Related]
14. Bilateral apocrine carcinoma of the breast. Molecular and immunocytochemical evidence for two independent primary tumours.
Schmitt FC; Soares R; Seruca R
Virchows Arch; 1998 Dec; 433(6):505-9. PubMed ID: 9870682
[TBL] [Abstract][Full Text] [Related]
15. Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer.
Saridakis A; Berger ER; Harigopal M; Park T; Horowitz N; Le Blanc J; Zanieski G; Chagpar A; Greenup R; Golshan M; Lannin DR
Ann Surg Oncol; 2021 Oct; 28(10):5610-5616. PubMed ID: 34426884
[TBL] [Abstract][Full Text] [Related]
16. Mixed Invasive Apocrine Papillary/Micropapillary Carcinoma of the Breast: Another Brick in the Triple-Negative Wall.
Cima L; Mirabassi N; Sartori C; Carbone FG; Morelli L; Cserni G; Barbareschi M
Int J Surg Pathol; 2021 Jun; 29(4):420-426. PubMed ID: 32909476
[TBL] [Abstract][Full Text] [Related]
17. IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.
Vranic S; Gurjeva O; Frkovic-Grazio S; Palazzo J; Tawfik O; Gatalica Z
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):413-6. PubMed ID: 21436679
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
Dellapasqua S; Maisonneuve P; Viale G; Pruneri G; Mazzarol G; Ghisini R; Mazza M; Iorfida M; Rotmensz N; Veronesi P; Luini A; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2013 Apr; 13(2):95-102. PubMed ID: 23245877
[TBL] [Abstract][Full Text] [Related]
19. Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature.
El Zein D; Hughes M; Kumar S; Peng X; Oyasiji T; Jabbour H; Khoury T
Clin Breast Cancer; 2017 Aug; 17(5):382-391. PubMed ID: 28529029
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]